Your AI-Trained Oncology Knowledge Connection!

Seema A. Bhat, MD

Seema A. Bhat, MD, is a hematologist at The Ohio State University Comprehensive Cancer Center—James; as well as an assistant professor in the Department of Internal Medicine in the Division of Hematology at The Ohio State University

Articles

Dr Bhat on Selecting Between Liso-Cel and Pirtobrutinib in Relapsed/Refractory CLL

Seema A. Bhat, MD

May 26th 2025

Seema A. Bhat, MD, discusses selecting between liso-cel and pirtobrutinib in relapsed/refractory CLL.

Dr Bhat on Choosing Between Pirtobrutinib and Liso-Cel for R/R CLL Management

Seema A. Bhat, MD

May 23rd 2025

Seema A. Bhat, MD, discusses disease features and patient characteristics that inform the choice between pirtobrutinib and liso-cel for CLL.

Dr Bhat on Using BTK Degraders and Bispecific Antibodies to Address Challenges With R/R CLL Management

Seema A. Bhat, MD

May 16th 2025

Seema A. Bhat, MD, discusses the ongoing development of BTK degraders and novel bispecific antibodies in relapsed/refractory CLL.

Dr Bhat on the Limitations of Current Treatments for Double-Refractory CLL

Seema A. Bhat, MD

May 12th 2025

Seema A. Bhat, MD, discusses the lack of highly effective treatment options for patients with double-refractory CLL.

Dr Bhat on the Influence of MPN Risk Stratification on Treatment Decision-Making

Seema A. Bhat, MD

March 20th 2025

Seema A. Bhat, MD, discusses typical treatment decisions for patients with myeloproliferative neoplasms based on risk stratification.

Dr. Bhat on ELEVATE-TN Results in Treatment-Naïve CLL

Seema A. Bhat, MD

October 21st 2020

Seema A. Bhat, MD, discusses the results of the phase 3 ELEVATE-TN trial in patients with treatment-naïve CLL.

Dr. Bhat on the FDA Approval of Acalabrutinib in CLL

Seema A. Bhat, MD

October 19th 2020

Seema A. Bhat, MD, discusses the approval of acalabrutinib in chronic lymphocytic leukemia based on data from the phase 3 ELEVATE-TN trial.

Dr. Bhat on the Potential for Time-Limited Combinations in CLL

Seema A. Bhat, MD

October 15th 2020

Seema A. Bhat, MD, discusses the potential for time-limited combination regimens in chronic lymphocytic leukemia.

Dr. Bhat on Emerging Targeted Therapies in CLL

Seema A. Bhat, MD

October 14th 2020

Seema A. Bhat, MD, emerging targeted therapies in chronic lymphocytic leukemia.

Dr. Bhat on the Rationale to Evaluate Acalabrutinib in CLL

Seema A. Bhat, MD

October 12th 2020

Seema A. Bhat, MD, discusses the rationale to evaluate acalabrutinib in chronic lymphocytic leukemia.

Dr. Bhat on the Combination of Ibrutinib Plus FCR in Treatment-Naïve CLL

Seema A. Bhat, MD

October 5th 2020

Seema A. Bhat, MD, discusses the combination of ibrutinib plus fludarabine, cyclophosphamide, and rituximab in young patients with treatment-naïve CLL.